← Back to Search

NMDA Receptor Antagonist

Ketamine for Stroke (QUEST-KETA Trial)

Phase 2 & 3

Waitlist Available

Research Sponsored by Lower Merion Neurology Research Foundation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Pre-stroke modified Rankin scale of 0-2

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up on day 1, day 4 or discharge whichever is earlier, and at 90 days

Awards & highlights

QUEST-KETA Trial Summary

This trial will test whether ketamine can help protect the brain from damage after a stroke.

Who is the study for?

This trial is for adults over 18 with acute ischemic stroke within the last 24 hours, confirmed by MRI. They must have been relatively independent before the stroke (modified Rankin scale of 0-2) and agree to participate. It's not for those with brain hemorrhage, pregnancy, known ketamine allergy, eligibility for certain other stroke treatments, psychiatric illness, seizure at symptom onset or severe uncontrolled high blood pressure.Check my eligibility

What is being tested?

The study tests if intravenous ketamine can protect the brain after an acute ischemic stroke by reducing harmful overactivity of nerve cells. Participants will receive either ketamine or placebo (normal saline), and some may get a sedative (midazolam injection) as part of this phase II trial.See study design

What are the potential side effects?

Ketamine might cause side effects like hallucinations, confusion, elevated blood pressure, nausea or vomiting. Midazolam could lead to drowsiness or breathing difficulties. The severity and occurrence vary among individuals.

QUEST-KETA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was independent in daily activities before my stroke.

QUEST-KETA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ on day 1, day 4 or discharge whichever is earlier, and at 90 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~on day 1, day 4 or discharge whichever is earlier, and at 90 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and on day 1, day 4 or discharge whichever is earlier, and at 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in weighted modified Rankin scale score between day 1 and 90 will be assessed.

Secondary outcome measures

All cause mortality

Barthel's index

Depression score using the PHQ9 questionnaire

+5 more

QUEST-KETA Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Study DrugExperimental Treatment2 Interventions

Will receive Ketamine infusion, and Midazolam (Versed).

Group II: PlaceboPlacebo Group2 Interventions

Will receive Normal saline infusion and Midazolam (Versed).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ketamine

FDA approved

Midazolam

FDA approved

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Lower Merion Neurology Research FoundationLead Sponsor

Media Library

Stroke Clinical Trial 2023: Ketamine Highlights & Side Effects. Trial Name: NCT03223220 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many test subjects are in this experiment?

"Unfortunately, this study is not taking any more participants at the moment. The clinical trial was first posted on 2023-01-01 and was last updated on 2022-10-12. However, there are 1123 other trials for wake-up stroke and 165 for Ketamine that are currently looking for patients."

Answered by AI

For what purposes is Ketamine commonly used?

"Ketamine is a medication commonly used to treat seizures and epileptic episodes. It can also help patients with amnesia, during certain therapeutic procedures, and who suffer from seizures."

Answered by AI

Are there any slots still open for subjects in this research project?

"Unfortunately, this particular study is not currently looking for new participants. However, there are 1123 other clinical trials actively recruiting patients with wake-up stroke and 165 studies related to Ketamine that are currently enrolling patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Quelling of Excitotoxicity in Acute Stroke With Ketamine

Sudhir Aggarwal MD, PhD, 2024. "Quelling of Excitotoxicity in Acute Stroke With Ketamine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03223220.

All > Toxicity